Posted by Michael Wonder on 14 Apr 2025
Thousands of people a year could benefit from new twice a day tablet for advanced breast cancer
11 April 2025 - We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
We've recommended capivasertib (Truqap; AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor positive HER2 negative breast cancer that has certain genetic mutations and has spread.
